Xencor: $707M cash; XmAb541 selectivity; plamotamab B-cell depletion; XmAb808 dose escalation; vudalimab enrollment done

Xencor Inc

Preliminary cash & marketable securities ~$707M at Dec 31, 2024, up from $697M in 2023; expected to fund ops into 2028.
New preclinical data shows XmAb541 (CLDN6 x CD3) selective binding to CLDN6 over CLDN9.
Plamotamab (CD20 x CD3) Phase 1 data shows deep peripheral B-cell depletion in lymphoma patients.
XmAb808 (B7-H3 x CD28) has resumed dose escalation in clinical study.
Enrollment completed in three ongoing vudalimab (PD-1 x CTLA-4) studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.